Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
SM-030 by DermBiont for Melasma (Chlosma): Likelihood of Approval
SM-030 is under clinical development by DermBiont and currently in Phase II for Melasma (Chlosma). According to GlobalData, Phase II...